A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
Aims: The primary goals of this randomized double-blind trial are to evaluate the safety and tolerability of the study medication (ALKS8700) and to compare the gastrointestinal (GI) tolerability of ALKS8700 with another MS medication, Dimethyl Fumarate (Tecfidera). The trial also aims to assess the utility of two GI symptom scales in assessing GI tolerability in adult subjects with relapsing remitting multiple sclerosis (RRMS).
Principal Investigator: Afif Hentati, MD
NorthShore Project Number: EH17-105
Contact: Please call 847.570.1439 with questions regarding the study
Open to Enrollment: Yes